Journal article

Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research

Shorn Goel, Jacquie Chirgwin, Prudence Francis, Robin Stuart-Harris, Joanna Dewar, Linda Mileshkin, Ray Snyder, Michael Michael, Bogda Koczwara

BREAST | CHURCHILL LIVINGSTONE | Published : 2011

Abstract

The management of HER2-positive metastatic breast cancer, a disease renowned for its aggressive natural history, has been revolutionized by the introduction of trastuzumab. Indeed, outcomes for patients with HER2-positive advanced breast cancer are now equivalent to, if not better than, those of their HER2-negative counterparts. Since the pivotal registration trial, a wealth of new clinical data has emerged regarding the use of trastuzumab in a variety of clinical contexts - adding to the evidence but also highlighting areas of uncertainly and debate. These include the optimal partner chemotherapy(ies) to trastuzumab; the effectiveness of combining trastuzumab with endocrine therapy; the ben..

View full abstract

Grants

Funding Acknowledgements

Dr Chirgwin has received conference travel support from Roche, GlaxoSmithKline, Sanofi Aventis, Schering Plough, and AstraZeneca, and has served on advisory boards for Hospira, Amgen, Novartis, and AstraZeneca; Dr Dewar has received conference travel support from Roche and GlaxoSmithKline; Dr Francis has received conference travel support from Roche, GlaxoSmithKline, Lilly, and Sanofi-Aventis; Dr Goel has received conference travel support from Roche, GlaxoSmithKline, Lilly, and Pfizer; Dr Koczwara has received research support from Roche and GlaxoSmithKline; Dr Snyder has served on advisory boards for Roche and GlaxoSmithKline; Michael, M., Mileshkin, L, Stuart-Harris, R.: None,